Version 1
: Received: 3 March 2022 / Approved: 8 March 2022 / Online: 8 March 2022 (08:24:35 CET)
Version 2
: Received: 9 March 2022 / Approved: 10 March 2022 / Online: 10 March 2022 (08:26:21 CET)
Version 3
: Received: 4 April 2022 / Approved: 5 April 2022 / Online: 5 April 2022 (10:17:10 CEST)
Parrish II, R.H.; Ashworth, L.D.; Löbenberg, R.; Benavides, S.; Cies, J.J.; MacArthur, R.B. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics 2022, 14, 1032. https://doi.org/10.3390/pharmaceutics14051032
Parrish II, R.H.; Ashworth, L.D.; Löbenberg, R.; Benavides, S.; Cies, J.J.; MacArthur, R.B. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics 2022, 14, 1032. https://doi.org/10.3390/pharmaceutics14051032
Parrish II, R.H.; Ashworth, L.D.; Löbenberg, R.; Benavides, S.; Cies, J.J.; MacArthur, R.B. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics 2022, 14, 1032. https://doi.org/10.3390/pharmaceutics14051032
Parrish II, R.H.; Ashworth, L.D.; Löbenberg, R.; Benavides, S.; Cies, J.J.; MacArthur, R.B. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics 2022, 14, 1032. https://doi.org/10.3390/pharmaceutics14051032
Abstract
The purpose of this work was to evaluate the suitability of recently US Food and Drug Administration (US-FDA) approved and marketed oral liquid, powder, or granule products for children in North America, to identify the next group of Active Pharmaceutical Ingredients (APIs) that have high potential for development as commercially available FDA-approved finished liquid dosage forms , and to propose lists of compounded nonsterile preparations (CNSPs) that should developed as commercially available FDA-approved finished liquid dosage forms as well as those that pharmacists should continue to compound extemporaneously. Through this identification and categorization process, the pharmaceutical industry, government, and the professions are encouraged to continue to work together to improve the likelihood that patients will receive high quality standardized extemporaneous CNSPs and US-FDA-approved products.
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
31 March 2022
Commenter:
Lucas Orth
The commenter has declared there is no conflict of interests.
Comment:
Great work with this update! One note: Three locations (Page 4, Paragraph 1; Table 1 title; and Table 2 title) reference "liquid" dosage forms, but Kapspargo 24h Sprinkle Capsule is one of the included products in the tables. While the sprinkle capsule is potentially helpful for some patients, metoprolol succinate is not to my knowledge available as a commercial liquid. Was this included in the liquid tables by mistake? (Table 2 does note that the fixed doses offered in this product are potentially not suitable).
Commenter: Richard Parrish
Commenter's Conflict of Interests: Author
Commenter: Lucas Orth
The commenter has declared there is no conflict of interests.